REDWOOD CITY, Calif. - Revolution Medicines Inc. (NASDAQ:RVMD) announced Monday that Steve Kelsey will transition from president of research and development to senior advisor to the chief executive officer, effective July 1.
Kelsey plans to retire from the company on January 4, 2027, according to a press release statement. The company anticipates appointing him to its Board of Directors upon his retirement.
Kelsey has served as president of research and development since March 2017, overseeing the company’s drug discovery and development, translational research, and manufacturing operations.
The company will implement a new leadership structure for its research and development functions beginning July 1. Alan Sandler, chief development officer, will continue to oversee the development department. Jan Smith, chief scientific officer, will oversee research activities. Xiaolin Wang will assume the role of executive vice president of integrated portfolio strategy and management, overseeing portfolio strategy, management, pharmaceutical development, and manufacturing.
Revolution Medicines develops targeted therapies for patients with RAS-addicted cancers. The company’s pipeline includes several RAS(ON) inhibitors in clinical development: daraxonrasib, elironrasib, zoldonrasib, and RMC-5127.The biotech company has seen remarkable investor interest, with shares trading at $163 near their 52-week high and delivering a 311% return over the past year. With a market capitalization of $34.7 billion, the stock currently appears overvalued according to InvestingPro analysis. Investors can access 13 additional ProTips and comprehensive financial metrics on the platform.
In other recent news, Revolution Medicines Inc. has been in the spotlight following the presentation of clinical trial results and analyst evaluations. The RASolute 302 trial, involving the company’s drug daraxonrasib, demonstrated significant results with an overall survival of 13.2 months and a progression-free survival of 7.3 months in the G12X subgroup. RBC Capital has raised its price target for Revolution Medicines to $182, citing the drug’s competitive edge in RAS oncology. UBS has maintained a Buy rating with a $175 price target, following promising data from a combination trial involving daraxonrasib. Stifel also reiterated a Buy rating, setting a higher price target of $215, impressed by the trial’s median progression-free survival and objective response rates.
TD Cowen has shown confidence in Revolution Medicines by reaffirming a Buy rating after the RASolute 302 trial met its primary endpoints. RBC Capital has reiterated an Outperform rating, expecting daraxibart to lead in the pancreatic ductal adenocarcinoma market. These developments indicate strong analyst support for Revolution Medicines, driven by its recent trial data and perceived market positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates RVMD every month against thousands of alternatives using 100+ financial metrics.It found Siemens Energy (+231.5%) and Sandisk (+189%) before the crowd did. Could RVMD be next—or is there a better opportunity in the same space?Don't wait to find out.